https://scholars.lib.ntu.edu.tw/handle/123456789/634807
標題: | Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in Asia | 作者: | Cheng, Ying CHIH-HSIN YANG Okamoto, Isamu Zhang, Li Hu, Jie Wang, Donglin Hu, Chengping Zhou, Jianying Wu, Lin Cao, Lejie Liu, Jiwei Zhang, Helong Sun, Hong Wang, Ziping Gao, Hongjun Yan, Yan Xiao, Suijun Lin, Jianxin Pietanza, M Catherine Kurata, Takayasu |
關鍵字: | cancer immunology; checkpoint inhibitors; immunotherapy | 公開日期: | 九月-2023 | 卷: | 15 | 期: | 13 | 來源出版物: | Immunotherapy | 摘要: | Aim: We pooled patient-level data from three randomized controlled studies to evaluate the combination of pembrolizumab plus chemotherapy in patients with untreated advanced/metastatic non-small-cell lung cancer (NSCLC) and programmed cell death ligand 1 (PD-L1) tumor proportion score <1% in East Asia. Methods: The analysis included 107 patients from China, Japan, Korea, Thailand and Taiwan (pembrolizumab plus chemotherapy, n = 56; chemotherapy alone, n = 51). Results: For pembrolizumab plus chemotherapy versus chemotherapy alone, median overall survival was 21.3 versus 12.6 months (HR, 0.55 [95% CI: 0.35-0.87]) and median progression-free survival was 8.4 versus 6.0 months (HR, 0.64 [95% CI: 0.43-0.96]). Conclusion: The analysis supports the use of pembrolizumab in combination with platinum-based chemotherapy for East Asian patients with PD-L1-negative, advanced NSCLC. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/634807 | ISSN: | 1750-743X 1750-7448 |
DOI: | 10.2217/imt-2023-0043 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。